Oncology
Breast Cancer Gets a New PI3K Pathway Option.
The FDA has approved gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative advanced breast cancer without a PIK3CA mutation. The approval creates a new option, but only if mutation testing is routine and trusted.
AI Pathology Starts Moving Toward Treatment Selection
AI Multiomics Moves Into the Trial Stratification Layer
A New CELMoD Raises the Bar in Relapsed Myeloma
IPM Alliance launches at the World Health Assembly in Geneva
IAPM Launches Oncology Pillar at ASCO: Closing the Gap Between Cancer Breakthroughs and Patient Access
WHA 2026: WHO resolution moves precision medicine onto the global health policy agenda
ASCO 2026: Pancreatic cancer gets its precision medicine moment
ASCO 2026: GI cancers are finally moving out of oncology’s blind spot
ASCO 2026: AI is entering cancer care before the rules are ready
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.